Europe Cardiovascular Therapeutic Drugs Market is worth USD 30.46 billion in 2018 and is estimated to grow at a CAGR of 2.05% reaching a value of USD 33.71 billion by 2023. There has been an increased usage of drug therapies with rising prevalence of cardiovascular diseases and evolvement of highly effective therapies helping the market for cardiovascular therapeutic drugs to grow.
Cardiovascular therapeutics drugs refers to the prescribed medicines and drugs for the diseases which are related to the functioning and treatment of heart and blood vessels. While cardiovascular diseases remains to be the leading cause of dead, the major reason causing cardiovascular problems include heart failure, blood clots, coronary artery diseases, high cholesterol and others.
The market is driven by a host of factors which includes rise in aging population, rise in per capita spending on healthcare and epidemic of general medical issues like obesity and diabetes. With cardiovascular disorders being the most common cause for morbidity and mortality, the market has a tremendous value and continue to do so in the coming years. However, there are a few restraints the market likes to overcome which includes rising costs for drug development and lowering of target population. And also, despite of high prevalence, drug development pipelines for cardiovascular disorders has been stagnant for a variety of reasons.
Europe cardiovascular therapeutic drugs market is divided on the basis of type of disease and drug class. The various diseases relating to the cardiovascular diseases includes thrombosis, Arteriosclerosis, Myocardial infarction, Cardiac arrhythmias, Peripheral artery disease, acute coronary syndrome, Coronary artery disease, hyperlipidaemia, hypertension, cardiac failure diseases and other cardiovascular diseases. On the basis of drug class, the market is further categorised into combination drug classes and monotherapies. Europe’s market is geographically segmented into United Kingdom, France, Germany, Italy and Spain.
The companies leading the cardiovascular therapeutic drugs market include Bristol-Myers Squibb (BMS), Novartis, AstraZeneca, Pfizer, Merck, Sanofi, Bayer, boehringer ingelheim, Takeda and Johnson & Johnson.
1. Introduction
1.1 Market Definition
1.2 Study Deliverables
1.3 Base Currency, Base Year and Forecast Periods
1.4 General Study Assumptions
2. Research Methodology
2.1 Introduction
2.2 Research Phases
2.2.1 Secondary Research
2.2.2 Primary Research
2.2.3 Econometric Modelling
2.2.4 Expert Validation
2.3 Analysis Design
2.4 Study Timeline
3. Overview
3.1 Executive Summary
3.2 Key Inferences
3.3 New Developments
4. Drivers, Restraints, Opportunities, and Challenges Analysis (DROC)
4.1 Market Drivers
4.2 Market Restraints
4.3 Key Challenges
4.4 Current Opportunities in the Market
5. Market Segmentation
5.1 By Disease
5.1.1 Arteriosclerosis
5.1.2 Cardiac arrhythmias
5.1.3 Myocardial infarction
5.1.4 Acute Coronary Syndrome
5.1.5 Peripheral artery disease
5.1.6 Coronary artery disease
5.1.7 Hypertension
5.1.8 Hyperlipidaemia
5.1.9 Thrombosis
5.1.10 Cardiac failure diseases
5.1.11 Others
5.2 By Drug Class
5.2.1 Monotherapies
5.2.2 Combination Therapies
6. Geographical Analysis
6.1 Introduction
6.2 U.K
6.3 Spain
6.2.4 Germany
6.2.5 Italy
6.2.6 France
7. Pipeline Product Analysis
7.1 Overview
7.2 Pipeline Development Landscape
7.3 Molecular Targets in the Pipeline
7.4 Clinical Trials
7.4.1 Failure Rate by Stage of Development, Indication, Molecule Type and Molecular Target
7.4.2 Clinical Trial Duration by Stage of Development, Indication, Molecule Type and Molecular Target
7.4.3 Clinical Trial Size by Stage of Development, Indication, Molecule Type and Molecular Target.
8. Strategic Analysis
8.1 PESTLE analysis
8.1.1 Political
8.1.2 Economic
8.1.3 Social
8.1.4 Technological
8.1.5 Legal
8.1.6 Environmental
8.2 Porter’s Five analysis
8.2.1 Bargaining Power of Suppliers
8.2.2 Bargaining Power of Consumers
8.2.3 Threat of New Entrants
8.2.4 Threat of Substitute Products and Services
8.2.5 Competitive Rivalry within the Industry
9. Market Leaders' Analysis
9.1 AstraZeneca
9.1.1 Overview
9.1.2 Product Analysis
9.1.3 Strategic Evaluation and Operations
9.1.4 Financial analysis
9.1.5 Legal issues
9.1.6 Recent Developments
9.1.7 SWOT analysis
9.1.8 Analyst View
9.2 Novartis
9.3 Bristol-Myers Squibb
9.4 Pfizer
9.5 Sanofi
9.6 Merck
9.7 Bayer
9.8 Takeda
9.9 Boehringer Ingelheim
9.10 Johnson & Johnson
10. Competitive Landscape
10.1 Market share analysis
10.2 Merger and Acquisition Analysis
10.3 Agreements, collaborations and Joint Ventures
10.4 New Product Launches
11. Expert Opinions
11.1 Market Outlook
11.2 Investment Opportunities
Appendix
a) List of Tables
b) List of Figures
